Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 Dec;60(6):938-41.
doi: 10.1038/bjc.1989.394.

Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry

C J Twelves  1 , S M O'Reilly, R E Coleman, M A Richards, R D Rubens
Affiliations

Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry

C J Twelves et al. Br J Cancer. 1989 Dec.

Abstract

Thirty-six consecutive patients with breast cancer and liver metastases with abnormal liver biochemistry were treated with epirubicin 25 mg m-2 i.v. weekly. No dose modification was made for abnormal liver biochemistry, but dose intensity was adjusted by delaying treatment according to myelosuppression. The UICC overall response rate according to UICC criteria was 11/36 (30%) and median response duration was 27 weeks. Liver biochemistry improved in a further seven patients. Treatment was well tolerated. Epirubicin given in this way is effective in patients with breast cancer and liver metastases. An initial deterioration in liver biochemistry may occur before there is a response to epirubicin.

PubMed Disclaimer

References

    1. Cancer Res. 1973 Feb;33(2):226-33 - PubMed
    1. Eur J Cancer Clin Oncol. 1988 Dec;24(12):1897-8 - PubMed
    1. Cancer. 1977 Aug;40(2):625-32 - PubMed
    1. Cancer. 1978 Jul;42(1):27-33 - PubMed
    1. Cancer Res. 1979 Nov;39(11):4503-6 - PubMed